Ventyx Biosciences to Participate in the Piper Sandler 37th Annual Healthcare Conference
Rhea-AI Summary
Ventyx Biosciences (Nasdaq: VTYX) said company executives will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York on Wednesday, December 3, 2025 from 4:00–4:25 PM ET. A live webcast will be available on the company's Investors and News webpage and a replay will be posted for 30 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction – VTYX
In the Dec 1 session, VTYX declined 6.20%, reflecting a notable negative market reaction. Argus tracked a trough of -5.5% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. Trading volume was elevated at 2.2x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 02 | Corporate & clinical update | Positive | -15.3% | Updated Phase 2 VTX2735 timelines and trial design, plus new senior advisors. |
| Dec 01 | Conference participation | Neutral | -6.2% | Announcement of Piper Sandler healthcare conference fireside chat and webcast details. |
| Nov 17 | Conference participation | Neutral | +2.7% | Jefferies Global Healthcare Conference fireside chat and webcast availability in London. |
| Nov 06 | Earnings report | Positive | +2.9% | Q3 2025 results with positive NLRP3 clinical data and funding runway commentary. |
| Oct 22 | Clinical trial update | Positive | +2.7% | Positive Phase 2 topline results for VTX3232 in obesity and cardiovascular risk factors. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
News tied to clinical data and earnings has generally seen positive alignment, while a recent clinical and corporate update drew a sharp negative divergence.
This announcement continues a series of visibility and pipeline updates for Ventyx. Recent news includes positive Phase 2 topline results for VTX3232 in obesity and cardiovascular risk factors on Oct 22, followed by Q3 2025 financial results and pipeline progress on Nov 06. The company has been active at investor conferences in November and December 2025, with fireside chats in London and New York. A Dec 02 clinical and corporate update on VTX2735 and trial plans coincided with a marked negative price reaction.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammation-mediated cardiovascular and neurodegenerative diseases, today announced that Company executives will participate in a fireside chat at the upcoming Piper Sandler 37th Annual Healthcare Conference in New York.
Piper Sandler 37th Annual Healthcare Conference details:
Fireside Chat
Date: Wednesday, December 3, 2025
Time: 4:00 – 4:25 PM ET
A live webcast of the event will be available In the Investors and News section of the Ventyx website at https://ventyxbio.com/. A webcast replay will also be available on this website after the conclusion of the event for 30 days.
About Ventyx Biosciences
Ventyx Biosciences is a clinical-stage biopharmaceutical company developing innovative oral therapies for patients inflammation-mediated cardiovascular and neurodegenerative diseases. Our expertise in medicinal chemistry, structural biology, and immunology enables the discovery of differentiated oral small molecule therapeutics for conditions with high unmet medical need, and our extensive experience in clinical development allows the rapid progression of these drug candidates through clinical trials.
Our portfolio of NLRP3 inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase 2 development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor that recently completed a Phase 2 study in participants with obesity and cardiovascular risk factors and a Phase 2a study in Parkinson’s disease. Our inflammatory bowel disease portfolio includes two Phase 2 compounds: tamuzimod (VTX002), an S1P1R modulator and VTX958, a TYK2 inhibitor.
For more information on Ventyx, please visit our website at https://ventyxbio.com.
Investor Relations Contact:
Alex Schwartz
Vice President, Investor Relations and FP&A
Ventyx Biosciences, Inc.
IR@ventyxbio.com
